Navigation Links
Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Date:10/17/2010

SAN CARLOS, Calif., Oct. 17 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.  These data were presented during the poster session entitled "Chronic and Cancer Pain" held today at the American Society of Anesthesiologists (ASA 2010) Annual Meeting on October 17, 2010 in San Diego, CA.

NKTR-181 was uniquely designed to cross the blood-brain barrier at a substantially slower rate than other opioid therapies.  With a reduced rate of entry into the CNS, NKTR-181 has the potential to eliminate not only the euphoria that underlies opioid abuse liability and dependence but also the serious CNS-related side effects of respiratory depression and sedation. The unique molecular design of the polymer drug conjugate also prevents conversion of NKTR-181 by the user into a rapid-acting abusable form of an opioid.  NKTR-181 is currently in IND-enabling studies and Nektar plans to begin Phase 1 clinical studies in the first part of 2011.  

"New therapeutics to manage chronic pain without the serious risks associated with existing opioids are desperately needed," said Lynn R. Webster, MD, Medical Director of Lifetree Clinical Research and Pain Clinic and President, Utah Academy of Pain Medicine.  "A novel opioid therapy, such as NKTR-181, with low abuse potential and fewer CNS-related side effects than existing opioids provides great promise for pain practitioners looking for safer, more effective pain management."

NKTR-181 Data Highlights from ASA 2010In a preclinical in vivo model of pain, NKTR-181 showed comparable analgesic efficacy to both oxycodone and morphine.   In self-administration studies in non-human
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Omeros Corporation ... its Investigational New Drug Application (IND) to evaluate ... the U.S. Food and Drug Administration (FDA). OMS824 ... in areas of the brain linked to a ... Huntington,s disease and schizophrenia. OMS824 has shown promising ...
(Date:5/23/2013)... YORK , May 23, 2013  Echo Pharma ... committed to waive down the Acceptance Threshold from 90 ... plus one Elan Share in accordance with the terms ... the conditions summarized below. Under the terms ... acquire Elan (NYSE: ELN ) for $12.50 ...
(Date:5/23/2013)... CHERTSEY , Engeland, May 23, 2013 ... goed voor mannen met lagere urinewegsymptomen geassocieerd met BPH ... BV, de Europese dochteronderneming van Astellas Pharma Inc, gebaseerd ... : 4503), kondigde vandaag aan dat het Nederlandse ... verleend voor VESOMNI in Nederland. De handelsvergunning ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 2Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 3Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 4
... /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex") (Nasdaq: ... healthcare products and services in the People,s Republic of ... financial results for the three and nine-month periods ended ... the market closes. Management will host a conference call ...
... March 4, 2011 A group of Canadian researchers led ... Osteoarthritis Research Unit at the University of ... trial in which they confirm, for the ... (qMRI), the disease modifying effects of chondroitin sulphate, a symptomatic ...
Cached Medicine Technology:Chindex International to Report Financial Results for the Three and Nine-Month Periods Ended December 31, 2010 2The Disease Modifying Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis Has Been Confirmed by MRI 2The Disease Modifying Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis Has Been Confirmed by MRI 3
(Date:5/23/2013)... Steven Reinberg HealthDay Reporter , , THURSDAY, May ... heartburn may be at increased risk for cancers of ... smoke or drink alcohol, a new study says. ... cancers while prescription medications such as Prilosec, Nexium and ... a controversy about whether heartburn contributes to cancers of ...
(Date:5/23/2013)... of older adults with dementia are less stressed ... dementia patients receive adult day services (ADS), according ... with and care for someone with dementia can ... professor and head, human development and family studies. ... provide caregivers with a much-needed break that can ...
(Date:5/23/2013)... YORK (May 23, 2013) -- Little is known about ... why response to treatments varies between patients. Now, a ... University Medical Center and SUNY Downstate Medical Center has ... asthma, showing that it is very different from other ... Medicine , reveals that an over-active gene linked in ...
(Date:5/23/2013)... researchers at Henry Ford Hospital found "substantial evidence" that ... spinal cord could hold the key to better functional ... new hope to those who suffer stroke, the leading ... victims recover some ability to voluntarily use their hands ... weakness on one side of their bodies, while a ...
(Date:5/23/2013)... It is Go Classy Tours / Caribbean Hideaways' ... Spa , a luxury nudist resort located in the Rivera ... International Naked Painting Party. Hidden Beach is a perfect location ... Hot Tub, Nude Bars & Nightclub and Nude Dinning. ... August 15th and go through August 18th, with the actual ...
Breaking Medicine News(10 mins):Health News:Chronic Heartburn May Raise Odds for Throat Cancer: Study 2Health News:Adult day services for dementia patients provide stress relief to family caregivers 2Health News:Researchers find common childhood asthma unconnected to allergens or inflammation 2Health News:Researchers find common childhood asthma unconnected to allergens or inflammation 3Health News:Regenerating spinal cord fibers may be treatment for stroke-related disabilities 2Health News:Regenerating spinal cord fibers may be treatment for stroke-related disabilities 3Health News:Hidden Beach, the Only Luxurious All-inclusive Nudist Resort in the Mexican Caribbean, to Host Social Exposure's Naked Painting Party, Announces Go Classy Tours 2
... INDIANAPOLIS, June 22 The board of directors of Eli Lilly and ... third quarter of 2009 of $0.49 a share on outstanding common stock. ... and second quarters and maintains the annual indicated dividend rate for 2009 ... September 10, 2009, to shareholders of record at the close of business ...
... blames physician misdiagnosis as the likely cause of apparent uptick ... A newly released study in the June 2009 British Journal ... the eastern United Kingdom has concluded that the much-hyped melanoma ... The study attributed the increase in melanoma diagnoses to heightened ...
... MIAMI, June 22 Now there,s a new ... time, suggests a new,study published in the July issue of ... drinking fat free milk in the,morning helped increase satiety, or ... the next meal, as compared with a fruit drink. The,milk ...
... , , , Personalized Medicine Meeting ... The Food and Drug Administration,s (FDA,s) ability to regulate genetic ... medicine stakeholders. , , Three-quarters of the attendees ... and Drug Law Institute (FDLI) and the American Association for ...
... NIH declines to attend field hearing exploring use of Recovery ... U.S. Senator Benjamin L. Cardin (D-MD ), chaired a ... Business and Entrepreneurship in Rockville, MD, entitled " Missed ... the hearing, local and national experts in biotechnology testified about ...
... Courage Center,s two camps, Camp Courage in Maple Lake ... camp schedule for people with disabilities. , , A recent ... participants (campers and MDA staff) who tested positive for H1N1 flu ... 6-12. Courage Center officials were contacted by the MDA locally three ...
Cached Medicine News:Health News:New Study Says Purported Melanoma Epidemic is Vastly Overstated 2Health News:Drinking Milk in the Morning May Help Stave off Lunchtime Hunger 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 3Health News:Cardin Calls on NIH to Utilize Small Businesses for Extramural Research Projects 2Health News:Courage Camps Maintain Summer Camp Schedule for Children and Adults With Disabilities 2
15" Monopolar Electrode, Ins., Hook Tip...
... versatile, dependable 990 frame the ... and completes the Nova diagnostic ... stands out due to its ... and its integral safety cut ...
... is an innovative and efficient inverted ... complements any research facility. Improved mechanics ... offers the TS100 binocular and TS100-F ... comes with a photo port that ...
... monochrome IR/DIC video camera. Olympus wide array of ... image quality and flexibility you need for an ... high-resolution, real-time image of your specimen that can ... TV. You can even record movies when these ...
Medicine Products: